Celadon affiliate commits $2.5M to Senti Biosciences after merger
What's the deal? An investor affiliated with Celadon PartnersDealroom has a profile for this one. Try Dealroom → has committed $2.5 million to buy newly issued common stock in Senti Biosciences (NASDAQ: SNTI), with proceeds designated to support the company following its merger.
Who's behind it? Celadon Partners SPVDealroom has a profile for this one. Try Dealroom → 24, Celadon Partners, LLC, and CPIF II-7 Limited collectively hold 25,748,890 Senti shares — a 54.6% activist stake disclosed under Schedule 13D. A related entity, CPIF II-7 Limited, is making the equity commitment.
How it works: The investor will buy shares at Nasdaq's minimum price, with the share count calculated by dividing $2.5 million by the per-share price and rounding down. Nearly all proceeds go to post-merger operations.
The fine print: The commitment hinges on a near-simultaneous closing of the transaction. Senti must keep at least $600,000 in cash or cash equivalents post-closing and take reasonable measures to maintain its Nasdaq Capital Market listing.
A registration rights agreement, granting customary demand and piggyback rights, must be executed at or before closing.
On the ownership math: The 54.6% figure is based on 47,116,644 shares projected to be outstanding — 31,144,754 common shares as of July 31, 2026, plus 15,971,890 shares tied to an immediate exchange of Initial Notes. That exchange depends on note issuance, stockholder approval, and completion under the Securities Purchase Agreement.
The signal: Celadon's combined majority stake and fresh capital tie the fund tightly to Senti's fortunes, giving the activist investor both control and a direct financial interest in the merged company's recovery.
Image credit: Generated with Gemini
